Lee's Pharmaceutical Holdings Limited functions as an investment holding company primarily focused on the development, manufacturing, and commercialization of pharmaceutical products within the People's Republic of China. The company's therapeutic scope is broad, addressing various medical conditions across diverse areas such as cardiovascular health, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. Its business operations are structured into two main segments: Proprietary and Generic Products, and Licensed-In Products. The Proprietary and Generic Products segment is responsible for producing and selling both its own internally developed medications and generic versions of established drugs. Notable products in this category include Livaracine, used to treat blood clots and deep vein thrombosis; Yallaferon for viral infections; Slounase, an agent for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection, also for deep vein thrombosis; and Sodium Phenylbutyrate Granules, which treat urea cycle disorders. Conversely, the Licensed-In Products segment manages the distribution and commercialization of pharmaceutical products obtained through licensing agreements with other companies. This extensive portfolio encompasses treatments such as Carnitene for carnitine deficiency; Aloxi and Sancuso for managing chemotherapy-induced nausea and vomiting; Bredinin, an immunosuppressant used in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil, which alleviates oral mucositis pain; Ferplex for iron deficiency anemia; and Gaslon N for gastric ulcers and gastritis. Additional offerings include Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution for primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan, indicated for Stage III and IV Hodgkin's disease; Omacor, containing Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik for Amyotrophic lateral sclerosis; Trittico for insomnia and depression; Unidrox for urinary and respiratory tract infections; the probiotics Dicoflor and VSL#3; and Zingo, a topical local analgesic. Lee's Pharmaceutical was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
—
Lee's Pharmaceutical Holdings Limited functions as an investment holding company primarily focused on the development, manufacturing, and commercialization of pharmaceutical products within the People's Republic of China. The company's therapeutic scope is broad, addressing various medical conditions across diverse areas such as cardiovascular health, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. Its business operations are structured into two main segments: Proprietary and Generic Products, and Licensed-In Products. The Proprietary and Generic Products segment is responsible for producing and selling both its own internally developed medications and generic versions of established drugs. Notable products in this category include Livaracine, used to treat blood clots and deep vein thrombosis; Yallaferon for viral infections; Slounase, an agent for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection, also for deep vein thrombosis; and Sodium Phenylbutyrate Granules, which treat urea cycle disorders. Conversely, the Licensed-In Products segment manages the distribution and commercialization of pharmaceutical products obtained through licensing agreements with other companies. This extensive portfolio encompasses treatments such as Carnitene for carnitine deficiency; Aloxi and Sancuso for managing chemotherapy-induced nausea and vomiting; Bredinin, an immunosuppressant used in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil, which alleviates oral mucositis pain; Ferplex for iron deficiency anemia; and Gaslon N for gastric ulcers and gastritis. Additional offerings include Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution for primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan, indicated for Stage III and IV Hodgkin's disease; Omacor, containing Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik for Amyotrophic lateral sclerosis; Trittico for insomnia and depression; Unidrox for urinary and respiratory tract infections; the probiotics Dicoflor and VSL#3; and Zingo, a topical local analgesic. Lee's Pharmaceutical was founded in 1994 and is headquartered in Sha Tin, Hong Kong.
—
Daily adjusted close
Lee's Pharmaceutical Holdings Limited functions as an investment holding company primarily focused on the development, manufacturing, and commercialization of pharmaceutical products within the People's Republic of China. The company's therapeutic scope is broad, addressing various medical conditions across diverse areas such as cardiovascular health, women's health, pediatrics, rare diseases, oncology, dermatology, obstetrics, and urology. Its business operations are structured into two main segments: Proprietary and Generic Products, and Licensed-In Products. The Proprietary and Generic Products segment is responsible for producing and selling both its own internally developed medications and generic versions of established drugs. Notable products in this category include Livaracine, used to treat blood clots and deep vein thrombosis; Yallaferon for viral infections; Slounase, an agent for hemostasis; Eyprotor for corneal ulcers; Treprostinil injection for pulmonary arterial hypertension; fondaparinux sodium injection, also for deep vein thrombosis; and Sodium Phenylbutyrate Granules, which treat urea cycle disorders. Conversely, the Licensed-In Products segment manages the distribution and commercialization of pharmaceutical products obtained through licensing agreements with other companies. This extensive portfolio encompasses treatments such as Carnitene for carnitine deficiency; Aloxi and Sancuso for managing chemotherapy-induced nausea and vomiting; Bredinin, an immunosuppressant used in renal transplantation; Centraxal Plus for acute otitis media with tympanostomy tubes; Episil, which alleviates oral mucositis pain; Ferplex for iron deficiency anemia; and Gaslon N for gastric ulcers and gastritis. Additional offerings include Intrarosa for vulvovaginal atrophy; Levocarnitine oral solution for primary and secondary carnitine deficiency; Mictonorm for urinary incontinence; Natulan, indicated for Stage III and IV Hodgkin's disease; Omacor, containing Omega-3-acid ethyl esters; Zanidip and Rasilez for hypertension; Readyfusor for post-operative pain management; Teglutik for Amyotrophic lateral sclerosis; Trittico for insomnia and depression; Unidrox for urinary and respiratory tract infections; the probiotics Dicoflor and VSL#3; and Zingo, a topical local analgesic. Lee's Pharmaceutical was founded in 1994 and is headquartered in Sha Tin, Hong Kong.